Amphastar P
$ 28.59
0.07%
11 Feb - close price
- Market Cap 1,328,364,000 USD
- Current Price $ 28.59
- High / Low $ 29.09 / 28.48
- Stock P/E 12.64
- Book Value 16.76
- EPS 2.26
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.15 %
- 52 Week High 32.69
- 52 Week Low 20.39
About
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
Analyst Target Price
$31.57
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-07 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-10 | 2024-02-29 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-02-28 |
| Reported EPS | 0.93 | 0.85 | 0.74 | 0.92 | 0.96 | 0.94 | 1.04 | 0.88 | 1.15 | 0.65 | 0.62 | 0.73 |
| Estimated EPS | 0.8523 | 0.74 | 0.6877 | 0.9383 | 1 | 0.77 | 0.96 | 0.93 | 0.69 | 0.56 | 0.48 | 0.41 |
| Surprise | 0.0777 | 0.11 | 0.0523 | -0.0183 | -0.04 | 0.17 | 0.08 | -0.05 | 0.46 | 0.09 | 0.14 | 0.32 |
| Surprise Percentage | 9.1165% | 14.8649% | 7.6051% | -1.9503% | -4% | 22.0779% | 8.3333% | -5.3763% | 66.6667% | 16.0714% | 29.1667% | 78.0488% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.91 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AMPH
2026-02-09 11:29:40
The New York State Common Retirement Fund increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 86.4% in the third quarter, acquiring an additional 41,800 shares to hold a total of 90,169 shares valued at approximately $2.40 million. Despite this institutional buying, company insiders have been net sellers, disposing of 34,808 shares worth $919,002 in the last three months. Analysts currently have an average "Hold" rating and a $31.00 price target for the stock, with Amphastar recently beating Q3 EPS estimates.
2026-02-06 09:29:40
Amphastar Pharmaceuticals Inc. recently experienced a 4.3 percentage point contraction in its adjusted operating margin due to rising expenses outpacing revenue, which is significant for a company with a smaller revenue base. This margin pressure, coupled with a high debt load, highlights challenges for the drugmaker, particularly concerning cost control and operational efficiency. Despite recent stock gains, there are varied investor opinions on its fair value, emphasizing the need for thorough analysis beyond herd mentality for potential investors.
2026-02-05 10:29:13
Amphastar Pharmaceuticals (NASDAQ:AMPH) recently saw its shares cross above the 50-day moving average, trading as high as $29.37 and closing at $28.61. This technical breakout follows a period where analysts have given the stock a "Hold" consensus rating with an average price target of $31.00. The company reported strong financial results with an earnings beat, showcasing revenue of $191.84 million against estimates of $186.90 million.
2026-01-28 14:59:49
SummerHaven Investment Management LLC has acquired a new stake of 38,200 shares, valued at approximately $1.02 million, in Amphastar Pharmaceuticals, Inc. The investment represents about 0.08% of the company. Amphastar Pharmaceuticals recently reported strong Q3 earnings, exceeding analyst estimates with an EPS of $0.93 and revenue of $191.8 million, though insiders have been net sellers in recent months.
2026-01-23 12:28:31
Amphastar Pharmaceuticals (NASDAQ: AMPH) has received an average "Hold" recommendation from eight analysts, with a mean 1-year price target of $31.00. Despite recent insider selling of over 35,000 shares, insiders still own 27.5% of the company. The company recently beat earnings expectations with EPS of $0.93 and revenue of $191.8 million, trading at a market cap of approximately $1.2 billion and a P/E ratio of ~11.6.
2026-01-21 06:12:00
This article analyzes Amphastar Pharmaceuticals Inc. (AMPH) using AI models to provide insights into its stock performance and rotational strategy timing. It identifies a near-term weak sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 15.7% gain. The piece also outlines three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) tailored to different risk profiles and holding periods, alongside multi-timeframe signal analysis.
